All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
Bookmark this article
On 21 November 2018, Tove Wästerlid from Karolinska Institute, Stockholm, SE, and colleagues, published in Blood a population analysis performed via the Swedish Lymphoma Registry (> 95% national coverage). This study focused on the outcomes and clinical characteristics of very elderly patients with major lymphoma types.
Very elderly lymphoma patients usually present with comorbidities and their frailty usually renders them ineligible for most clinical trials. Thus, treatment regimens are limited and not thoroughly researched in this population. The aim of the study here was to evaluate, specifically in individuals aged ≥ 85, lymphoma outcomes and treatment choices. The primary endpoint of the study was overall survival (OS).
The results of this real-world analysis in Swedish very elderly lymphoma patients, indicate that in DLBCL and MZL current active treatments offer a significantly superior survival outcome, when compared to no active treatment administration. According to the authors, this study is the largest population-based lymphoma analysis for that age group and provides valuable information on clinical disease management and how it can be improved. Updated outcome analysis from this study, and in combination with data from the Danish Lymphoma Registry will be presented at the 60th American Society of Hematology Meeting, 2018, San Diego, CA, USA.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Your opinion matters
Phase II study assesses the use of rituximab and bendamustine in frail, elderly DLBCL patients
The authors concluded that they found the combination of bendamustine and rituximab to be a good treatment option showing “promising activity” for elderly...
Prof. Marek Trněný | ASH 2017 | R-CHOP plus rituximab maintenance in elderly patients
59th ASH Annual Meeting and Exposition, 9 - 12 Dec 2017, Atlanta, GA Professor Marek Trněný Charles University Hospital, Prague, CZ Topic: Will 8xR-CHOP...
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox